6533b7cffe1ef96bd125866f
RESEARCH PRODUCT
Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies.
Ramiro JoverCelia P. Martinez-jimenezJosé V. CastellMaría José Gómez-lechónsubject
PharmacologyCell fusionCell Culture TechniquesDrug Evaluation PreclinicalReproducibility of ResultsGeneral MedicineBiologyToxicologyCell biologyCell LineXenobioticsmedicine.anatomical_structureBiochemistryDownregulation and upregulationCell cultureHepatocytemedicineHepatic stellate cellHepatocytesAnimalsHumansProgenitor cellCellular modelDrug metabolismCell Line Transformeddescription
Gaining knowledge on the metabolism of a drug, the enzymes involved and its inhibition or induction potential is a necessary step in pharmaceutical development of new compounds. Primary human hepatocytes are considered a cellular model of reference, as they express the majority of drug-metabolising enzymes, respond to enzyme inducers and are capable of generating in vitro a metabolic profile similar to what is found in vivo. However, hepatocytes show phenotypic instability and have a restricted accessibility. Different alternatives have been explored in the past recent years to overcome the limitations of primary hepatocytes. These include immortalisation of adult or fetal human hepatic cells by means of transforming tumour virus genes, oncogenes, conditionally immortalised hepatocytes, and cell fusion. New strategies are currently being used to upregulate the expression of drug-metabolising enzymes in cell lines or to derive hepatocytes from progenitor cells. This paper reviews the features of liver-derived cell lines, their suitability for drug metabolism studies as well as the state-of-the-art of the strategies pursued in order to generate metabolically competent hepatic cell lines.
year | journal | country | edition | language |
---|---|---|---|---|
2006-03-24 | Expert opinion on drug metabolismtoxicology |